Investors & Media

Overview

Webcast ImageWebcast
bluebird bio EHA Data Review Conference Call (Replay)
06/23/17 at 8:00 a.m. ET
bluebird bio EHA Data Review Conference Call
Friday, June 23, 2017 8:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Corporate Profile

bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. The company’s objective is to develop and bring to market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe and effective treatment options. Headquartered in Cambridge, Massachusetts, bluebird bio has operations in the U.S. and Europe.

stock quote

NASDAQ: BLUE (common stock)

Refresh Quote
ExchangePriceChange (%)Volume
NASDAQ GS (US Dollar)
$109.10
 Stock is Up 2.20 (2.06%)
2,911,137
Data provided by Nasdaq. Minimum 15 minutes delayed.